|
1
|
Sytkowski JA: Erythropoietin: Blood, Brain
and Beyond. Wiley-VCH; Boston, MA: 2004, View Article : Google Scholar
|
|
2
|
Debeljak N and Sytkowski AJ: EpoR.
UCSD-Nature Molecule Pages. 2007, View Article : Google Scholar
|
|
3
|
Jelkmann W and Wagner K: Beneficial and
ominous aspects of the pleiotropic action of erythropoietin. Ann
Hematol. 83:673–686. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Debeljak N and Sytkowski AJ:
Erythropoietin: new approaches to improved molecular designs and
therapeutic alternatives. Curr Pharm Des. 14:1302–1310. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Szenajch J, Wcislo G, Jeong JY, Szczylik C
and Feldman L: The role of erythropoietin and its receptor in
growth, survival and therapeutic response of human tumor cells:
from clinic to bench - a critical review. Biochim Biophys Acta.
1806:82–95. 2010.PubMed/NCBI
|
|
6
|
Acs G, Acs P, Beckwith SM, et al:
Erythropoietin and erythropoietin receptor expression in human
cancer. Cancer Res. 61:3561–3565. 2001.PubMed/NCBI
|
|
7
|
Arcasoy MO, Amin K, Karayal AF, et al:
Functional significance of erythropoietin receptor expression in
breast cancer. Lab Invest. 82:911–918. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eschbach JW, Egrie JC, Downing MR, Browne
JK and Adamson JW: Correction of the anemia of end-stage renal
disease with recombinant human erythropoietin. Results of a
combined phase I and II clinical trial. N Engl J Med. 316:73–78.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schrijvers D, De Samblanx H and Roila F:
ESMO Guidelines Working Group: Erythropoiesis-stimulating agents in
the treatment of anaemia in cancer patients:
Erythropoiesis-stimulating agents in the treatment of anaemia in
cancer patients: ESMO Clinical Practice Guidelines for use. Ann
Oncol. 21(Suppl 5): v244–v247. 2010. View Article : Google Scholar
|
|
10
|
Latini R, Brines M and Fiordaliso F: Do
non-hemopoietic effects of erythropoietin play a beneficial role in
heart failure? Heart Fail Rev. 13:415–423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moore EM, Bellomo R and Nichol AD:
Erythropoietin as a novel brain and kidney protective agent.
Anaesth Intensive Care. 39:356–372. 2011.PubMed/NCBI
|
|
12
|
Sytkowski AJ: The neurobiology of
erythropoietin. Cell Mol Neurobiol. 31:931–937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brines M, Grasso G, Fiordaliso F, et al:
Erythropoietin mediates tissue protection through an erythropoietin
and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA.
101:14907–14912. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noren NK and Pasquale EB: Paradoxes of the
EphB4 receptor in cancer. Cancer Res. 67:3994–3997. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jackson DB, Stein M, Voss H, Brock S,
Danes CG and Sood A: Tissue protective erythropoietin receptor
(nepor) and methods to use. Patent WO 2009/068677. Filed November
28, 2008; issued April 18, 2012.
|
|
16
|
Kumar SR, Singh J, Xia G, et al: Receptor
tyrosine kinase EphB4 is a survival factor in breast cancer. Am J
Pathol. 169:279–293. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Henke M, Laszig R, Rube C, et al:
Erythropoietin to treat head and neck cancer patients with anaemia
undergoing radiotherapy: randomised, double-blind,
placebo-controlled trial. Lancet. 362:1255–1260. 2003. View Article : Google Scholar
|
|
18
|
Leyland-Jones B, Semiglazov V, Pawlicki M,
et al: Maintaining normal hemoglobin levels with epoetin alfa in
mainly nonanemic patients with metastatic breast cancer receiving
first-line chemo-therapy: a survival study. J Clin Oncol.
23:5960–5972. 2005. View Article : Google Scholar
|
|
19
|
Sytkowski AJ: Does erythropoietin have a
dark side? Epo signaling and cancer cells. Sci STKE.
2007.pe382007.PubMed/NCBI
|
|
20
|
Schnitt SJ: Classification and prognosis
of invasive breast cancer: from morphology to molecular taxonomy.
Mod Pathol. 23(Suppl 2): S60–S64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thomas P, Pang Y, Filardo EJ and Dong J:
Identity of an estrogen membrane receptor coupled to a G protein in
human breast cancer cells. Endocrinology. 146:624–632. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thomas P: Characteristics of membrane
progestin receptor alpha (mPRalpha) and progesterone membrane
receptor component 1 (PGMRC1) and their roles in mediating rapid
progestin actions. Front Neuroendocrinol. 29:292–312. 2008.
View Article : Google Scholar
|
|
23
|
Levin ER: Integration of the extranuclear
and nuclear actions of estrogen. Mol Endocrinol. 19:1951–1959.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bjornstrom L and Sjoberg M: Mechanisms of
estrogen receptor signaling: convergence of genomic and nongenomic
actions on target genes. Mol Endocrinol. 19:833–842. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vasudevan N and Pfaff DW:
Membrane-initiated actions of estrogens in neuroendocrinology:
emerging principles. Endocr Rev. 28:1–19. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pedram A, Razandi M, Sainson RC, Kim JK,
Hughes CC and Levin ER: A conserved mechanism for steroid receptor
translocation to the plasma membrane. J Biol Chem. 282:22278–22288.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar P, Wu Q, Chambliss KL, et al: Direct
interactions with G α i and G βγ mediate nongenomic signaling by
estrogen receptor α. Mol Endocrinol. 21:1370–1380. 2007.
|
|
28
|
Hammes SR and Levin ER: Minireview: Recent
advances in extra-nuclear steroid receptor actions. Endocrinology.
152:4489–4495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Levin ER: G protein-coupled receptor 30:
estrogen receptor or collaborator? Endocrinology. 150:1563–1565.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pelekanou V, Kampa M, Kafousi M, et al:
Erythropoietin and its receptor in breast cancer: correlation with
steroid receptors and outcome. Cancer Epidemiol Biomarkers Prev.
16:2016–2023. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Larsson AM, Jirstrom K, Fredlund E, et al:
Erythropoietin receptor expression and correlation to tamoxifen
response and prognosis in breast cancer. Clin Cancer Res.
15:5552–5559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Volgger B, Kurz K, Zoschg K, et al:
Importance of erythropoetin receptor expression in tumour tissue
for the clinical course of breast cancer. Anticancer Res.
30:3721–3726. 2010.PubMed/NCBI
|
|
33
|
Filardo EJ, Quinn JA and Sabo E:
Association of the membrane estrogen receptor, GPR30, with breast
tumor metastasis and transactivation of the epidermal growth factor
receptor. Steroids. 73:870–873. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kampa M, Pelekanou V and Castanas E:
Membrane-initiated steroid action in breast and prostate cancer.
Steroids. 73:953–960. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pelekanou V, Notas G, Sanidas E, Tsapis A,
Castanas E and Kampa M: Testosterone membrane-initiated action in
breast cancer cells: Interaction with the androgen signaling
pathway and EPOR. Mol Oncol. 4:135–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Notas G, Kampa M, Pelekanou V and Castanas
E: Interplay of estrogen receptors and GPR30 for the regulation of
early membrane initiated transcriptional effects: a pharmacological
approach. Steroids. 77:943–950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xiao Z, Carrasco R, Kinneer K, et al:
EphB4 promotes or suppresses Ras/MEK/ERK pathway in a
context-dependent manner: implications for EphB4 as a cancer
target. Cancer Biol Ther. 13:630–637. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hevir N, Trošt N, Debeljak N and Rižner
TL: Expression of estrogen and progesterone receptors and estrogen
metabolizing enzymes in different breast cancer cell lines. Chem
Biol Interact. 191:206–216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bustin SA, Benes V, Garson JA, et al: The
MIQE guidelines: minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kutuk O, Arisan ED, Tezil T, Shoshan MC
and Basaga H: Cisplatin overcomes Bcl-2-mediated resistance to
apoptosis via preferential engagement of Bak: critical role of
Noxa-mediated lipid peroxidation. Carcinogenesis. 30:1517–1527.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Abramoff MD, Magelhaes PJ and Ram SJ:
Image Processing with ImageJ. Biophotonics International. 11:36–42.
2004.
|
|
42
|
Jelkmann W, Bohlius J, Hallek M and
Sytkowski AJ: The erythropoietin receptor in normal and cancer
tissues. Crit Rev Oncol Hematol. 67:39–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vivacqua A, Bonofiglio D, Recchia AG, et
al: The G protein-coupled receptor GPR30 mediates the proliferative
effects induced by 17beta-estradiol and hydroxytamoxifen in
endometrial cancer cells. Mol Endocrinol. 20:631–646. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Albanito L, Madeo A, Lappano R, et al: G
protein-coupled receptor 30 (GPR30) mediates gene expression
changes and growth response to 17beta-estradiol and selective GPR30
ligand G-1 in ovarian cancer cells. Cancer Res. 67:1859–1866. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kanda N and Watanabe S: 17beta-estradiol
stimulates the growth of human keratinocytes by inducing cyclin D2
expression. J Invest Dermatol. 123:319–328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Michalides R, Griekspoor A, Balkenende A,
et al: Tamoxifen resistance by a conformational arrest of the
estrogen receptor alpha after PKA activation in breast cancer.
Cancer Cell. 5:597–605. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shou J, Massarweh S, Osborne CK, et al:
Mechanisms of tamoxifen resistance: increased estrogen
receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J
Natl Cancer Inst. 96:926–935. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ignatov A, Ignatov T, Roessner A, Costa SD
and Kalinski T: Role of GPR30 in the mechanisms of tamoxifen
resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat.
123:87–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liang K, Esteva FJ, Albarracin C, et al:
Recombinant human erythropoietin antagonizes trastuzumab treatment
of breast cancer cells via Jak2-mediated Src activation and PTEN
inactivation. Cancer Cell. 18:423–435. 2010. View Article : Google Scholar
|
|
50
|
Cui X, Schiff R, Arpino G, Osborne CK and
Lee AV: Biology of progesterone receptor loss in breast cancer and
its implications for endocrine therapy. J Clin Oncol. 23:7721–7735.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Trošt N, Juvan P, Serša G and Debeljak N:
Contrasting effect of erythropoietin on breast cancer cell response
to cisplatin induced cytotoxicity. Radiol Oncol. 46:213–225.
2012.PubMed/NCBI
|
|
52
|
Hui L, Zheng Y, Yan Y, Bargonetti J and
Foster DA: Mutant p53 in MDA-MB-231 breast cancer cells is
stabilized by elevated phospholipase D activity and contributes to
survival signals generated by phospholipase D. Oncogene.
25:7305–7310. 2006. View Article : Google Scholar : PubMed/NCBI
|
